Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has been shown to be effective for the treatment of advanced RCC following treatment failure with the first-line drugs sunitinib or sorafenib. This evidence concerns the gene MTOR and renal cell carcinoma.